H.C. Wainwright Upgrades Dicerna Pharmaceuticals (DRNA) to Buy
Get Alerts DRNA Hot Sheet
Rating Summary:
5 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Join SI Premium – FREE
H.C. Wainwright analyst Ed Arce upgraded Dicerna Pharmaceuticals (NASDAQ: DRNA) from Neutral to Buy with a price target of $21.00 (from $14.00).
Arce said their positive investment rationale is predicated on broad progress across the pipeline. We see three fundamental drivers to our positive view, leading us to upgrade DRNA shares to Buy, from Neutral previously.
(1) Lead drug DCR-PHXC
(2) Second program DCR-HBVS
(3) Several other RNAi programs slated for outlicensing
For an analyst ratings summary and ratings history on Dicerna Pharmaceuticals click here. For more ratings news on Dicerna Pharmaceuticals click here.
Shares of Dicerna Pharmaceuticals closed at $14.82 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Upgrades Citizen Watch (7762:JP) to Buy
- Citi Downgrades Malaysia Airports Holdings Bhd (MAHB:MK) (MYPRF) to Neutral
- Teleperformance (TEP:FP) (TLPFY) PT Lowered to EUR125 at RBC Capital, 'perceived risk profile makes it a no-fly zone for many investors'
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change, UpgradesRelated Entities
H.C. Wainwright, Ed ArceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!